"We are very much looking forward to the results of ART's First-In-Man study. The key features of ART's next-generation bioresorbable stent are that it is made of non-aggressive material and is designed to have a programmed transitory presence in order to facilitate natural remodeling," concluded Mr Van der Leest.

ART is developing bioresorbable coronary polymer stents that promote the natural remodeling of an injured artery after angioplasty. The company's technology is based on intellectual property originating from three esteemed institutions: the Cleveland Clinic; the French national research institute, CNRS (Centre National de Recherche Scientifique), Montpellier, France; and, Descartes University, Paris.